Korean

National Institute of Health Korea Vaccine Resarch Center

Mobile Menu

Vaccine Development Support

Support work

* Move the screen left or right to see the full contents.
Scope of vaccine development support - Proceeds through the stages of national policy establishment, candidate material discovery stage, and vaccine development stage.
National policy establishment stage
Candidate discovery stage
Vaccine development stage
Export stage
Vaccine development roadmap Discovery of effective substances Discovery of lead substances Non-clinical clinical Product approval PQ support
Establishment of vaccine development
policy and roadmap		 Exploration and Excavation Derivation of lead substances through efficacy evaluation Non-clinical efficacy evaluation Verification of efficacy and safety in humans MFDS’s approval WTO PQ support
Priority Target Candidate Vaccine

  • Discovery and evaluation of candidate substances

  • Non-clinical research

  • Infrastructure support· technology transfer

  • Clinical application and commercialization

support system
Vaccine Clinical Research Division
  • Conducts non-clinical studies and evaluates efficacy.
  • Establishes strategies to support vaccine development in private organizations and manage difficulties
  • Upgrades and provides facilities, equipment, and system infrastructure
Vaccine Clinical Research Department
  • Supports clinical research and network construction for commercialization of infectious disease vaccines
  • Supports vaccine clinical research and efficacy evaluation
Pathogen Resource Management Division
  • Provides specialized pathogen resources
  • Supports conservation and deposition of high-quality pathogen resources
Supported Testing Methods
* Move the screen left or right to see the full contents.
Validity evaluation support test method table - Provides information on items such as classification, binding antibody assay (ELISA), neutralizing antibody assay (PRNT, FRNT), and T cell immune response assay (ELISPOT)
Types Binding Antibody Analysis
(ELISA)		 Neutralizing Antibody Test T-Cell Immune Response Test
(ELISPOT)
PRNT FRNT
characteristic
  • 1. Duration (2 days)
  • 2. Available in Biological Safety Level 2 (BSL-2) facilities
  • 3. Analysis using specific equipment
  • 4. Quantitative analysis possible
  • 5. High sensitivity and specificity
  • 1. Duration (5-6 days)*Including cell culture period
  • 2. Required in BSL-3 facilities
  • 3. Visual analysis
  • 4. Quantitative analysis possible
  • 5. Gold standard for neutralizing antibody measurement
  • 1. Duration (3 days)*Including cell culture period
  • 2. Required in BSL-3 facilities
  • 3. Analysis using specific equipment
  • 4. Quantitative analysis possible
  • 5. Rapidity and reproducibility
  • 1. Duration (2-3 days)
  • 2. Available in a biosafety level 2 facility
  • 3. Analysis using specific equipment
  • 4. Quantitative analysis possible
  • 5. High sensitivity and specificity
  • 6. PBMC isolation required